PTK2 and melanoma: While our study here provides evidence for FAK inhibition in reducing melanoma progression, in part, through decreased CDK4/6 expression and cell cycle arrest, more work is needed to evaluate the potential of FAK-Is in treating melanoma either as a monotherapy or in combination with BRAF, MEK, or immune checkpoint therapies.